NDAORALTABLET
Approved
Oct 2006
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
8/8 — Comprehensive
JANUVIA (sitagliptin) by Merck & Co. is dipeptidyl peptidase 4 inhibitors [moa]. Approved for type 2 diabetes mellitus. First approved in 2006.
JANUVIA (sitagliptin) is an oral tablet approved in October 2006 as a dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus. It works by inhibiting the enzyme DPP-4, which prolongs the activity of incretin hormones that regulate blood glucose levels in a glucose-dependent manner. JANUVIA is typically used as monotherapy or in combination with other antidiabetic agents and represents an important non-insulin treatment option in the diabetes care continuum.
$4.1BPart D
1.1 years to LOEMechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Indications (1)
Clinical Trials (20)
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator
Started Jun 2024
34 enrolled
Healthy Subjects
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator
Started Apr 2024
34 enrolled
Healthy Subjects
Semaglutide vs Sitagliptin
Started Oct 2022
140 enrolled
Liver Transplant; ComplicationsDiabetes MellitusNASH - Nonalcoholic Steatohepatitis+1 more
Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
Started Mar 2022
46 enrolled
Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)
A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
Started Jul 2019
1,441 enrolled
Diabetes Mellitus, Type 2
Worked on JANUVIA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.